492 related articles for article (PubMed ID: 32268131)
1. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.
Inoue Y; Kaner RJ; Guiot J; Maher TM; Tomassetti S; Moiseev S; Kuwana M; Brown KK
Chest; 2020 Aug; 158(2):646-659. PubMed ID: 32268131
[TBL] [Abstract][Full Text] [Related]
2. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
4. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
[No Abstract] [Full Text] [Related]
5. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
[TBL] [Abstract][Full Text] [Related]
6. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
7. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
8. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
Nili M; Singer D; Hanna M
BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
[TBL] [Abstract][Full Text] [Related]
9. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis.
Aoshima Y; Enomoto Y; Muto S; Meguro S; Kawasaki H; Kosugi I; Fujisawa T; Enomoto N; Inui N; Nakamura Y; Suda T; Iwashita T
Lung; 2021 Jun; 199(3):289-298. PubMed ID: 33770226
[TBL] [Abstract][Full Text] [Related]
10. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases.
Nakashima T; Omori K; Namba M; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Respir Med; 2023 Jun; 212():107224. PubMed ID: 37003499
[TBL] [Abstract][Full Text] [Related]
11. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.
Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
Olson AL; Gifford AH; Inase N; Fernández Pérez ER; Suda T
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578336
[TBL] [Abstract][Full Text] [Related]
13. Human epididymis protein 4 is a new biomarker to predict the prognosis of progressive fibrosing interstitial lung disease.
Nishiyama N; Masuo M; Nukui Y; Tateishi T; Kishino M; Tateishi U; Morota K; Ohbo K; Miyazaki Y
Respir Investig; 2021 Jan; 59(1):90-98. PubMed ID: 32919933
[TBL] [Abstract][Full Text] [Related]
14. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
Albera C; Verri G; Sciarrone F; Sitia E; Mangiapia M; Solidoro P
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572422
[TBL] [Abstract][Full Text] [Related]
15. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
18. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne].
Villeneuve T; Prévot G; Lintz F; Mourin G; Ferry G; Bousquet E; Perelroizen H; Boghanim T; Faviez G; Noël-Savina E; Collot S; Le Borgne A; Didier A
Rev Mal Respir; 2021 Dec; 38(10):972-979. PubMed ID: 34629221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
